¹⁸F-RGD PET/CT and Systemic Inflammatory Biomarkers Predict Outcomes of Patients With Advanced NSCLC Receiving Combined Antiangiogenic Treatment.

ABSTRACT:

Background

The aim of this study was to evaluate ¹⁸F-AlF-NOTA-PRGD2 positron emission tomography/computed tomography (¹⁸F-RGD PET/CT) and serum inflammation biomarkers for predicting outcomes of patients receiving combined antiangiogenic treatment for advanced non-small cell lung cancer (NSCLC).

Methods

Patients with advanced NSCLC underwent ¹⁸F-RGD PET/CT examination and provided blood samples before treatments commenced. PET/CT parameters included maximum standard uptake value (SUVmax) and mean standard uptake value (SUVmean), peak standard uptake value (SUVpeak) and metabolic tumor volume (MTV) for all contoured lesions. Biomarkers for inflammation included pretreatment neutrophil-to-lymphocyte ratio (PreNLR), pretreatment platelet-to-lymp

SUBMITTER: Liu J 

PROVIDER: S-EPMC8212050 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature